Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Leiomyosarcoma × olaparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 34 Breast Neoplasms 26 Triple Negative Breast Neoplasms 17 Prostatic Neoplasms 17 Fallopian Tube Neoplasms 11 Neoplasms 9 Pancreatic Neoplasms 7 Fanconi Anemia, Complementation Group D1 7 Endometrial Neoplasms 7 Glioma 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Sarcoma 5 Neoplasm Metastasis 5 Cholangiocarcinoma 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Lymphoma, Non-Hodgkin 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Osteosarcoma 3 Lung Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Carcinosarcoma 3 Carcinoma, Renal Cell 3 Wilms Tumor 2

Interventions

Gemcitabine 13 Doxorubicin 8 Docetaxel 7 Trabectedin 5 pazopanib 4 Nivolumab 4 Temozolomide 3 Specimen Handling 3 Sorafenib 3 rucaparib 2 pembrolizumab 2 liposomal doxorubicin 2 durvalumab 2 brostallicin 2 Sunitinib 2 Radiotherapy 2 Radiation Dose Hypofractionation 2 Magnetic Resonance Spectroscopy 2 Letrozole 2 Ifosfamide 2 Dacarbazine 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tremelimumab 1 talimogene laherparepvec 1 sotigalimab 1 soblidotin 1 saracatinib 1 rubitecan 1 romidepsin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03851614 2026-02-09

DAPPER

University Health Network, Toronto

Phase 2 Active not recruiting

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡